Alzheimer's disease is associated with removal of the synaptic protein ADAM10

Alzheimer's disease is characterized by the accumulation of neurotoxic β-amyloid peptide (A-beta). ADAM10, a protein that resides in the neural synapses, has previously been shown to prevent the formation of A-beta.

In this issue of the Journal of Clinical Investigation, Monica Di Luca and colleagues at the University of Milan in Milan, Italy, report that ADAM10 is removed from synapses through association with the protein AP2.

Strikingly, the association between ADAM10 and AP2 was increased in homogenates from Alzheimer's disease (AD) patients compared to healthy controls.

was shown to influence the level and activity of ADAM10 in synapses and its association with AP2.

These studies identify pathological mechanisms associated with AD that control the localization of proteins at the synapse.

More information: Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease J Clin Invest. doi:10.1172/JCI65401

add to favorites email to friend print save as pdf

Related Stories

New approach to Alzheimer's therapy

Jul 30, 2010

Researchers from the German Centre for Neurodegenerative Diseases and the Ludwig-Maximilians-Universitat in Munich have shown that the ADAM10 protein can inhibit the formation of beta-amyloid, which is responsible for Alzheimer's ...

Upending textbook science on Alzheimer's disease

Nov 23, 2009

Alzheimer's disease is caused by the build-up of a brain peptide called amyloid-beta. That's why eliminating the protein has been the focus of almost all drug research pursuing a cure for the devastating neurodegenerative ...

Recommended for you

Putting dementia carers in control

Sep 18, 2014

Experts will explore how improved support and powers for people caring for loved-ones with dementia can improve quality of life for both patients and carers around the UK.

Lilly, AstraZeneca team up on Alzheimer's drug

Sep 16, 2014

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

User comments